Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-954 for Postoperative Gastrointestinal Dysfunction
NCT03827655Phase 2Completed
- Sponsor
- Takeda
- Start
- Mar 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of felcisetrag in Postoperative gastrointestinal dysfunction (POGD) (5 arms), sponsored by Takeda. Primary endpoint: Time From End of the Surgery to Resolution of Upper and Lower Gastrointestinal (GI) Function Postsurgery as Assessed by the Investigator. Started Mar 2019; status: completed.
02
Drugs
felcisetrag
03
Conditions
Postoperative gastrointestinal dysfunction (POGD)
Beyond the preview
Go deeper on NCT03827655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827655.